期刊
PATHOGENS
卷 10, 期 3, 页码 -出版社
MDPI
DOI: 10.3390/pathogens10030314
关键词
Candida albicans; candidiasis; 1,3,4-oxadiazole; drug discovery; antifungal agents; drug resistance; toxicity; biofilm
类别
资金
- National Council for Scientific and Technological Development (CNPq) [552276/2011-1]
- Coordination for the Improvement of Higher Education Personnel (CAPES) [001]
LMM6 demonstrated high efficacy against clinical C. albicans isolates, synergistic effects with other antifungal drugs, fungicidal and anti-biofilm activity, as well as no acute toxicity, suggesting its potential as a future treatment for invasive candidiasis.
Candida albicans is the most common species isolated from nosocomial bloodstream infections. Due to limited therapeutic arsenal and increase of drug resistance, there is an urgent need for new antifungals. Therefore, the antifungal activity against C. albicans and in vivo toxicity of a 1,3,4-oxadiazole compound (LMM6) was evaluated. This compound was selected by in silico approach based on chemical similarity. LMM6 was highly effective against several clinical C. albicans isolates, with minimum inhibitory concentration values ranging from 8 to 32 mu g/mL. This compound also showed synergic effect with amphotericin B and caspofungin. In addition, quantitative assay showed that LMM6 exhibited a fungicidal profile and a promising anti-biofilm activity, pointing to its therapeutic potential. The evaluation of acute toxicity indicated that LMM6 is safe for preclinical trials. No mortality and no alterations in the investigated parameters were observed. In addition, no substantial alteration was found in Hippocratic screening, biochemical or hematological analyzes. LMM6 (5 mg/kg twice a day) was able to reduce both spleen and kidneys fungal burden and further, promoted the suppresses of inflammatory cytokines, resulting in infection control. These preclinical findings support future application of LMM6 as potential antifungal in the treatment of invasive candidiasis.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据